Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Residual Effects of Zolpidem Tartrate Extended Release and Eszopiclone Vs Placebo

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00283790
Recruitment Status : Completed
First Posted : January 30, 2006
Last Update Posted : April 3, 2008
Information provided by:

Brief Summary:
Investigation of Psychomotor and Cognitive Residual Effects of Single Oral Doses of Zolpidem Tartrate Extended Release 12.5 mg and Eszopiclone 3 mg Compared to Placebo in Healthy Young Volunteers, Using Flurazepam 30 mg as an External Comparator

Condition or disease Intervention/treatment Phase
Insomnia Drug: zolpidem tartrate Phase 4

Detailed Description:
This is a crossover study, with 4 different treatments (Ambien, Lunesta, placebo, and flurazepam). The flurazepam arm always comes last due to the long washout period associated with it. The other 3 arms are randomized.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Investigation of Psycliomotor and Cognitive Residual Effects After Single Oral Doses of Zolpidem Tartrate Extended Release 12.5 mg and Eszopielone 3 mg Compared to Placebo in Healthy Young Volunteers, Using Plurazepam 30 mg As An External Comparator
Study Start Date : January 2006
Study Completion Date : April 2006

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Psychometric testing:
  2. Critical Flicker Fusion (CFF)
  3. Choice Reaction Time (CRT)
  4. Immediate and Delayed Recall of Supraspan Word Lists (WRI and WRD)
  5. Compensatory Tracking Task (CTT)
  6. Digit Symbol Substitution Test (DSST)

Secondary Outcome Measures :
  1. Efficacy Measures:
  2. Sleep measures from Morning Sleep Questionnaire
  3. Residual Effects of Zolpidem Tartrate Extended Release and Eszopiclone Vs Placebo
  4. Leeds Sleep Evaluation Questionnaire (LSEQ)
  5. Bond & Lader (B&L) Visual Analog Scale
  6. Health Outcome Measures
  7. Sleep Treatment Questionnaire

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes


  1. Healthy male and female subjects aged between 18 and 45 years.
  2. Usual bedtime between 21:00 and 01:00
  3. Body mass index (BMI) between 18 and 32 kg/m2.
  4. Certified as healthy by a comprehensive clinical assessment (detailed medical history and a complete physical examination).
  5. Laboratory tests within the normal range of the laboratory (hematology, biochemistry, urinalysis) or within the acceptable range per agreement between investigator and sponsor.
  6. Negative urine pregnancy test for females (to be confirmed at screening and prior to every dose of study medication)
  7. Women must use a medically acceptable form of contraception (steroidal contraceptive, double-barrier, or intra-uterine device) during the entire study period, or they must be surgically sterilized or post-menopausal. If abstinent, women must agree to use double-barrier contraception throughout the study period should they become sexually active.
  8. Written informed consent signed


  1. Presence or history of clinically relevant cardiovascular, hepatic, pulmonary, gastrointestinal, renal, metabolic, hematological, neurologic or psychiatric disease, any acute infectious disease or signs of acute illness, and myasthenia gravis
  2. Any disorder initiating or maintaining sleep such as Obstructive Sleep Apnea, Insomnia, Restless Leg Syndrome, Periodic Limb Movement Disorder, Circadian Rhythm Disorder and Parasomnia
  3. Frequent headaches and/or migraine, recurrent nausea and/or vomiting (more than twice a month).
  4. Symptomatic hypotension, whatever the decrease of blood pressure, or asymptomatic postural hypotension defined by a decrease in SBP equal to or greater than 20 mmHg within two minutes when changing from the supine to the standing position.
  5. History of hypersensitivity to zolpidem, eszopiclone, or flurazepam.
  6. Use of any medication within one month prior to study start, except occasional use of acetaminophen or ibuprofen.
  7. History of drug abuse during prior twelve months
  8. Excessive consumption of xanthine-based beverages (more than 6 cups or glasses per day) or unable to stop consumption during the overnight study periods.
  9. Inability to communicate or cooperate with the investigator because of a language problem, poor mental status, or impaired cerebral status.
  10. Positive results of urine drug screen testing (amphetamines, benzodiazepines, cannabis, barbiturates, cocaine, opiates, antidepressants).
  11. Any use of dietary, herbal, and/or fitness/body-building supplements (with the exception of vitamins)
  12. Current use of tobacco products including cigarettes, cigars, pipes, or chewing tobacco, current participation in a smoking cessation program, or discontinuation of smoking within 3 months prior to screening
  13. Subject is currently participating in another clinical trial with an investigation product/device (or within 30 days of screening).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00283790

Layout table for location information
United States, New Jersey
Bridgewater, New Jersey, United States, 08807
Sponsors and Collaborators
Layout table for investigator information
Study Director: Phyllis Diener Sanofi
Layout table for additonal information Identifier: NCT00283790    
Other Study ID Numbers: PM_L_0289
First Posted: January 30, 2006    Key Record Dates
Last Update Posted: April 3, 2008
Last Verified: April 2008
Additional relevant MeSH terms:
Layout table for MeSH terms
Sleep Initiation and Maintenance Disorders
Sleep Disorders, Intrinsic
Sleep Wake Disorders
Nervous System Diseases
Mental Disorders
Sleep Aids, Pharmaceutical
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
GABA-A Receptor Agonists
GABA Agonists
GABA Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action